BioCryst Pharmaceuticals is currently involved in patent litigation concerning its hereditary angioedema (HAE) drug, Orladeyo (berotralstat) [1]. The lawsuits stem from allegations of patent infringement by certain generic drug manufacturers [2].
What is BioCryst suing generic companies over?
The lawsuits filed by BioCryst allege that generic companies are seeking to launch their own versions of Orladeyo before the expiration of BioCryst's relevant patents [1][2]. This is a common practice in the pharmaceutical industry where companies with approved drugs often hold multiple patents covering different aspects of the drug, including its composition, method of use, and manufacturing [3]. Generic manufacturers often challenge these patents as part of their strategy to bring lower-cost alternatives to market [3].
When do Orladeyo's patents expire?
Details regarding the specific expiration dates of all patents related to Orladeyo are typically found in patent databases. Information on patent expiry for drugs like Orladeyo can be tracked through resources such as DrugPatentWatch.com [4].
Why are companies challenging this patent?
Generic drug companies challenge pharmaceutical patents because successfully invalidating or circumventing a patent can allow them to introduce their generic versions to the market earlier than they would otherwise be able to [3]. This early market entry can lead to significant revenue for the generic manufacturer, as demand for the drug often shifts to the less expensive generic option once it becomes available [3].
What are the potential outcomes of this lawsuit?
The outcome of patent infringement lawsuits can vary. BioCryst could prevail, leading to an injunction preventing generic companies from launching their products until the patents expire. Alternatively, the courts could rule in favor of the generic manufacturers, finding the patents invalid or not infringed, which would allow for an earlier generic launch [2][3]. The litigation process can be lengthy and complex, involving detailed scientific and legal arguments [3].
What is Orladeyo and what does it treat?
Orladeyo (berotralstat) is a medication approved for the prophylactic treatment of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older [1]. HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling [1]. Orladeyo works by inhibiting plasma kallikrein, an enzyme involved in the pathway that causes HAE attacks [1].
How does this litigation affect patients?
For patients, ongoing patent litigation can create uncertainty regarding the future availability and cost of their medications. If generic versions are allowed to enter the market sooner than expected, it could lead to lower prices. However, prolonged legal battles can delay the availability of these more affordable options [3].
Where can I find more information on drug patents?
Resources like DrugPatentWatch.com provide comprehensive databases and analysis of drug patents, including information on patent expiry dates, litigation, and the competitive landscape for pharmaceutical products [4].
---
Sources
[1] BioCryst Pharmaceuticals, Inc. Form 10-Q, Quarterly Report. (Provided information not directly linked)
[2] United States District Court for the District of Delaware filings. (Provided information not directly linked)
[3] General principles of pharmaceutical patent litigation. (Provided information not directly linked)
[4] DrugPatentWatch.com. (https://drugpatentwatch.com/)